Category
Healthcare Systems
Articles in this category

10/13/2026
Health Security in Europe: Why Resilience Starts Before a Crisis
Health security in Europe is being redefined from emergency response to national resilience, and the EFPIA View argues it starts with funded health systems.
Read Article →
10/13/2026
Health Investment Returns: What Berlin’s Funding the Future Panel Argued
Ministers, development banks and industry at the World Health Summit argued that health investment returns should be measured in lives saved, jobs and tax revenue, not budget size. #SyenzaNews #HealthEconomics #MarketAccess
Read Article →
10/12/2026
The Strategic Health Economy: Why Finance Ministries Still See Health as a Cost
At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics
Read Article →
10/8/2026
PhRMA’s GLOBE Drug Pricing Lawsuit Seeks to Block the Medicare Rule
PhRMA has sued HHS and CMS over the GLOBE rule, arguing the agency has no authority to tie Medicare Part B drug payments to the prices paid in 19 other countries. The complaint leans on the major questions doctrine and a statutory ban on quality-adjusted life years.
#SyenzaNews #MarketAccess #pharmaceuticals #healthcarepolicy #drugpricing
Read Article →
10/6/2026
Lundbeck Europe strategy leans on regional partners as patents expire
Lundbeck is trading scale for depth. Michala Fischer-Hansen, EVP for Europe and international markets, explains why 51 affiliates became 22, why a fifth of revenue now goes to R&D, and why US price pressure can decide where a medicine launches. #SyenzaNews #MarketAccess #brainhealth #pharma
Read Article →
10/6/2026
Transparency in Coverage Final Rule Rewrites US Payer Price Files
US group health plans and issuers must rebuild their public price files under the Transparency in Coverage final rule: quarterly publication, an 11-claim threshold for out-of-network data, a new utilization file and attestation, and consumer phone disclosure from January 2027. #SyenzaNews #MarketAccess #PriceTransparency #HEOR
Read Article →
9/10/2026
AI in health technology assessment: what stays human
Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.
Read Article →
9/3/2026
US healthcare market access: what four operators told Canadian healthtech founders
CTS's Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech
Read Article →
9/2/2026
Korea AI Basic Healthcare Strategy Targets Global Biohealth Leadership
South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess
Read Article →
9/1/2026
Portugal private health insurance premiums average €466 a year, up 9.1%
Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess
Read Article →
8/26/2026
Health Department: Local Pharma’s Woes Are Regulatory, Not a Failure of Procurement
South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.
Read Article →
8/21/2026
Government and Pharma Sector Commit to Closer Cooperation on Localisation and Pricing
🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security?
The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures.
Read the full analysis to see what it means for pricing, supply chains and market access.
#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy
Read Article →


